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Objective. To evaluate the early and late major amputation and survival rates and related risk factors in diabetic patients
with critical limb ischemia (CLI).
Design. Retrospective study.
Methods. Revascularization feasibility, major amputation, survival rate and related risk factors were recorded in 564
diabetic patients consecutively hospitalized for CLI from 1999 to 2003 and followed until June 2005.
Results. Peripheral angioplasty (PTA) was carried out in 420 (74.5%), bypass graft (BPG) in 117 (20.7%) patients. In 27
(4.8%) patients both PTA and BPG were not possible. Twenty-three above-the-ankle amputations (4.1%) were performed at
30 days: 6 in PTA patients, 3 in BPG patients, 14 in non revascularized patients. In the follow-up of 558 patients (98.9%),
62 repeated PTAs and 9 new BPGs, 32 new major amputations (16 in PTA patients, 14 in BPG patients and 2 in non-
revascularized patients) were performed. Major amputation was associated with absence of revascularization (OR 35.9,
p< 0.001, CI 12.9e99.7), occlusion of each of the three crural arteries (OR 8.20, p¼ 0.022, CI 1.35e49.6), wound in-
fection (OR 2.1, p¼ 0.004 CI 1.3e3.6), dialysis (OR 4.7, p¼ 0.001 CI 1.9e11.7) increase in TcPO2 after revasculariza-
tion (OR 0.80, p< 0.001 CI 0.74e0.87).
One hundred seventy three patients died during follow-up and this was associated with age (HR 1.05, p< 0.001 CI
1.03e1.07), history of cardiac disease (HR 2.16, p< 0.001 CI 1.53e3.06), dialysis (HR 3.52, p< 0.001 CI 2.08e
5.97), absence of revascularization (HR 1.68, p< 0.001, CI 1.29e2.19) and impaired ejection fraction (HR 1.08,
p< 0.001, CI 1.05e1.09).
Conclusions. In diabetic patients with CLI the revascularization is feasible in most cases and allows a low rate of early
major amputation. This rate is higher in the follow-up period. Major amputation is very high in patients where revascu-
larization is not feasible while the high mortality rate is due to the serious comorbidities observed in these patients.
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tion; Survival.Studies on diabetic patients with peripheral arterial
disease support the effectiveness of revasculariza-
tion,1e3 however very few studies report the out-
comes of patients unsuitable for revascularization.4
We do not know any study in diabetic population
that used the diagnostic criteria of critical limb ische-
mia (CLI) proposed in 2000 by TransAtlantic Inter-
Society Consensus (TASC).5
The purpose of this study is to evaluate the out-
comes of diabetic patients with TASC criteria of CLI.
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URL: http://www.diabeticfoot.it1078–5884/000484 + 07 $35.00/0  2006 Elsevier Ltd. All rights reseWe report the feasibility of revascularization with
peripheral angioplasty (PTA) or bypass graft (BPG),
the early major amputation rate, the incidence of redo
vascular procedures and of new major amputations,
the survival rate and related risk factors for amputation
and survival in diabetic patients consecutively hospi-
talized for CLI.
Materials and Methods
Protocol
All diabetic patients referred to our Diabetic Foot Cen-
tre were assessed for the presence of sensory-motor
neuropathy and peripheral arterial occlusive disease.rved.
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of vibration perception threshold> 25 V at biothesi-
ometer, insensitivity in >5/9 foot points at Semmes-
Weinstein 10 g filament, and absence of Achilles’ tendon
reflex. Peripheral arterial disease was suspected if one
foot pulse was reduced or absent, ankle-pressure was
<70 mmHg when assessable, transcutaneous oxygen
tension (TcPO2) at the dorsum of the foot was
<50 mmHg, and significant obstructions were present
at duplex scanning. All patients with these parame-
ters were referred to an angiographic study and, if ob-
struction> 50% of vessel diameter was present, PTA
was performed in the same session.6 In patients un-
suitable for PTA a by-pass graft (BPG) was consid-
ered. The patients in whom PTA or BPG were not
possible, received a therapy with prostanoids (alpros-
tadil-a-ciclodextrine 60e120 mgr/day) and percutane-
ous sympathectomy with phenol injection under CT
guidance.
In patients in whom therapies did not relieve the
rest pain or the gangrene was extended above the
Chopart joint, major amputation was performed.
For all patients, antalgic medication, TcPO2 and
ankle pressure were reassessed 5 days after the PTA,
BPG, sympathectomy or prostanoids infusion.
Limb salvage
In patients complaining of rest pain without foot ulcer,
the disappearance of pain with discontinuation of ant-
algic therapy was considered to be a successful limb
salvage. In patients with foot ulcer we considered
limb salvage successful when the ulcer healed and
plantar stand was maintained, even when achieved
by tarsal-metatarsal amputation7,8 and the patient
was able to walk without crutches or artificial leg.
Conversely, any above-the-ankle amputation was
considered a failure (major amputation).
Complications
Any event that required specific medical or surgical
treatment or prolonged hospital stay following PTA
or BPG was recorded and considered a complication.
Haematoma formation at the puncture site was con-
sidered not significant unless necessitating either
surgery and/or packed red blood cell transfusion.
Follow-up
After hospital discharge all patients with foot ulcer
were examined weekly until ulcer healing. All pa-
tients were provided with extra-deep rocker shoeswith soft thermoformable leather and customized
insoles. Restenosis after PTA was suspected when
pain or an ulcer recurred. In these situations ankle-
pressure and TcPO2 were reassessed and duplex scan-
ning was performed.9 If ankle pressure and TcPO2 were
significantly worse (<15% of the post-PTA value) and
Duplex scanning was positive, the patient underwent
a new angiographic evaluation and a further PTA, if
possible, or a BPG, if PTA impossible, was performed.
Morphological restenosis was not investigated since
in absence of rest pain or ulcer reappearance we do
not perform any revascularization, therefore we con-
sider it clinically irrelevant.10 BPGs were followed
according to the vascular surgery protocol.11 The graft
patency was assessed with clinical examination and
ultrasound study at 30 days, 3,6,12 months and there-
after every 6 months.
For every invasive treatment (PTA, BPG, sympa-
thectomy, surgical operation on the foot) the written
informed consent form was obtained from the patient.
PTA clinical restenoses, BPG closures, repeat vas-
cular procedures, new above-the-ankle amputations,
vital status as well as date and cause of deaths were
recorded.
Statistical methods
Descriptive statistics were reported as average values
and 1 standard deviation (SD) for continuous vari-
ables and as percentages for discrete variables.
The relationship among the considered variables
and the risk of above-the-ankle amputation was eval-
uated by multiple logistic regression and data were
reported with odds ratio (OR) and 95% CI. The Cox
regression model was adopted and Hazard Ratio
(HR) for the tested variables was reported in order
to check the association of patients characteristics
and the life time lasted from the entry in the study un-
til the death or study closure. The time to the major
amputation and death was studied by applying the
Kaplan Meier approach and product/limit curves
were built up.
The Stata 7.0 software package (Statistics/Data
Analysis, Stata Corporation, 4905 Lakeway Drive,
College Station, Texas 77845 USA, 800-STATA-PC) was
used.
Results
Patient population and treatment
From January 1, 1999 to December 31, 2003, 902
diabetic patients were consecutively hospitalized for
foot ulcer and/or rest pain.Eur J Vasc Endovasc Surg Vol 32, November 2006
486 E. Faglia et al.567 patients in whom our diagnostic protocol indi-
cated the presence of CLI were referred to an angio-
graphic study. Three patients had no angiographic
evidence of stenoses> 50% of vessel diameter, and
were excluded from the analysis. Thus the study pop-
ulation included 564 (62.5%) patients.
Revascularization was performed in 537 (95.2%)
patients.
PTA was performed in 420 (74.5%) patients. Table 1
reports the number of treated stenoses and occlusions,
the number of stents placed in every artery of the
ischemic limb and the rate of successful PTA
procedures.
A BPG was performed in 117 (20.7%) patients.
The BPG was axillo-femoral in one patient, femoral-
popliteal (16 PTFE, 45 vein graft) in 61 patients,
femoral-infrapopliteal (17 PTFE, 40 vein graft) in
57 patients. In 22 of these 117 patients a combined
procedure, PTA plus BPG, was performed: in 10
patients an iliac PTA and femoral-popliteal BPG,
in 12 patients femoral-popliteal BPG and an infra-
popliteal PTA.
In 27 (4.8%) patients neither a PTA nor a BPG was
possible due to high surgical risk or lack of outflow. In
all these patients a treatment with prostanoids was
started, but was immediately stopped in 5 patients
for hypotension and in 2 for angina. In 5 patients
a percutaneous chemical sympathectomy was also
performed, while in the remaining patients this proce-
dure was not considered appropriate due to the pres-
ence of a serious cardiopathy and other comorbidities
(Table 2).
The ankle-pressure could not be measured in 297
(52.7%) patients, because of the absence of both tibial
arteries in 105 patients or due to the presence of arte-
rial calcifications in 192 patients.Eur J Vasc Endovasc Surg Vol 32, November 2006In-hospital mortality
Four patients died during their hospital stay. Three
BPG patients died: 1 for pneumonia, 1 for acute myo-
cardial infarction and 1 for congestive heart failure.
One non-revascularized patient died suddenly the
night following the angiographic study.
Early limb salvage
Of the 537 revascularized patients, in 85 patients with
rest pain without foot ulcer the pain disappeared and
the antalgic medication was discontinued. In 443
patients with foot ulcers a complete healing of the
lesions occurred with dressing or minor amputation.
Nine (1.7%) major amputations were carried out at
30 days. Two above- and 4 below-the-knee amputa-
tions (1.4%) were performed in PTA patients, in 5
for extensive infection of surgical wound of a Chopart
amputation, and in 1 for acute distal thrombosis after
PTA not suitable for surgical revascularization. Of
these six major amputations, three were performed
in patients treated without stent and three in patients
treated with stent, without significant difference
( p¼ 0.358). Three (2.6%) above-the-knee amputations
were performed in BPG patients with crural by-pass,
2 with PTFE and 1 with venous conduit following
acute non treatable graft closure.
Of the 27 non-revascularized patients, in 2 patients
the foot lesion healed with dressing whereas in 14
patients major amputation (10 above- and 4 below-
the-knee) was performed at 30 days for rest pain and
extensive gangrene. In the other 11 patients the foot
lesion did not heal but there was not worsening, the
pain decreased but did not disappear and the antalgic
medication was reduced but not discontinued.PTA and BPG complications
Table 3 reports the non fatal complications in PTA and
BPG patients.
Follow-up
558 (98.9%) patients, 415 of the PTA group, 116 of the
BPG group and 27 of non revascularized group, were
Table 1. Number of treated stenoses and occlusions, their percent of TASC non eligible, number of stents placed in every artery and
percent of success of PTA procedures
Artery Stenoses Length> 4 cm Successful pta Stents Occlusions Length> 2 cm Successful pta Stents
Iliac trunk 31 10 (32.3%) 31 (100%) 19 4 2 (50.0%) 4 (100%) 4
Femoral 146 97 (66:4) 146 (100%) 8 78 51 (65.4%) 78 (100%) 40
Popliteal 112 41 (36.6%) 112 (100%) 1 36 16 (44.4%) 36 (100%) 18
Anterior tibial 91 80 (87.9%) 76 (83.5%) e 257 232 (90.3%) 63 (24.5%) 6
Posterior tibial 57 45 (78.9%) 46 (80.7%) e 291 262 (90.0%) 40 (13.7%) 7
Peroneal 125 89 (71.2%) 100 (80.0%) e 124 77 (62.1%) 32 (25.8%) 4
A concomitant femoral-popliteal and crural PTA was performed in 151 patients: in 116 with angioplasty of one crural artery, more than one
in 35 patients.
487Early and Five-year Amputation and Survival Rate of Diabetic PatientsTable 2. Demographic and clinical characteristics of study population (N[ 564) in revascularized patients with PTA and BPG, and in
revascularized and non revascularized patients
Variables PTA
n¼ 420
BPG
n¼ 117
p Revascularized
patients n¼ 537
Non revascularized
patients n¼ 27
p
Age (years) 69.7 9.4 69.8 9.6 0.910 69.8 9.5 76.7 10.4 0.001
Females (n) 148 (35.2%) 37 (31.6%) 0.467 185 (34.9%) 13 (48.1%) 0.146
Insulin therapy (n) 255 (60.7%) 73 (62.4%) 0.742 328 (61.1%) 14 (51.9%) 0.338
Diabetes duration (years) 17.7 11.4 14.9 9.9 0.020 17.1 11.1 13.4 10.0 0.013
Sensory-motor neuropathy (n) 343 (81.7%) 98 (83.8%) 0.600 441 (82.1%) 24 (88.9%) 0.367
Creatinine (mg/dl) (n¼ 532) 1.29 0.5 1.25 0.4 0.470 1.28 0.5 1.15 0.36 0.208
Dialysis (n) 24 (5.7%) 8 (7.0%) 0.650 32 (5.9%) e e
Antihypertensive therapy (n) 304 (72.4%) 72 (61.5%) 0.240 376 (70.0%) 20 (74.1%) 0.653
Cardiac disease (n) 225 (53.6%) 64 (54.7%) 0.566 289 (53.8%) 24 (88.9%) 0.003
Ejection fraction (%, n¼ 323) 49.1 10.8 49.6 10.1 0.700 49.2 10.5 38.34 8.4 0.001
History of stroke (n) 55 (13.1%) 19 (16.2%) 0.380 74 (13.8%) 9 (33.3%) 0.005
Wagner grade (n) 0 66 (15.7%) 19 (16.2%) 0.822 85 (15.8%) 3 (11.1%) 0.840
1 64 (15.2%) 14 (12.0%) 78 (14.5%) 5 (18.5%)
2 59 (14.0%) 14 (12.0%) 73 (13.6%) 5 (18.5%)
3 41 (9.8%) 11 (9.4%) 52 (9.7%) 3 (11.1%)
4 190 (45.2%) 59 (50.4%) 249 (46.4%) 11 (40.7%)
Infected ulcer (n) 270 (64.3%) 75 (64.1%) 0.971 345 (64.2%) 17 (63.0%) 0.892
TcPO2 before the treatment (mmHg) 15.3 11.9 10.3 10.6 0.001 13.8 11.2 7.0 8.1 0.001
TcPO2 after the treatment (mmHg) 44.9 12.1 38.9 12.0 0.690 41.6 12.1 11.4 8.6 0.001followed from January 1st 1999 until June 30th 2005.
The mean follow-up was 3.4 1.3 years.
CLI recurrence during follow-up
A first episode of clinical restenosis in the PTA group
occurred in 76 (18.3%) patients. The cumulative pa-
tency rate at 5 years was 78% (CI 71e83%). PTA pro-
cedures were successfully repeated in 62 (81.6%)
patients and 1 patient died suddenly the night after
PTA. In the remaining 14 patients a further PTA was
not feasible, and 8 patients underwent a BPG.
Non-treatable graft closure occurred in 22 (18.8%)
patients of the BPG group. The cumulative patency
rate at 5 years was 77% (CI 67e85%).
Table 3. Non fatal complications and their treatment in revascular-
ized patients (N[ 537)
PTA patients (N[ 420) N Treatment
Myocardial infarction 1 Intensive care unit
Angina 1 Medical treatment
Cardiac arrhythmia 1 Intensive care unit
Left ventricular failure 1 Medical treatment
Chest pain 1 Investigation, no treatment
Acute renal failure 1 Medical treatment without
dialysis
Haematoma at the access site 2 Transfusion
1 Investigation without therapy
Access site pseudoaneurysms 3 Surgical treatment
Thrombosis 5 Thrombolysis effectiveness
1 Above-the-knee amputation
BPG patients (N[ 117) N Treatment
Thrombosis 8 Thrombectomy
3 Above the knee amputation
Venous fistula 1 Surgical ligatureMajor amputation during follow-up
Thirty-two major amputations were performed. Three
above- and 13 below- the-knee amputations were per-
formed in the PTA group, 14 because of recurrence of
rest pain and extensive gangrene due to non-treatable
restenosis and 2 because of osteomyelitis of the heel.
Ten above- and 4 below-the-knee amputations were
performed in the BPG group because of non-treatable
occlusion of the graft and 1 patient died during hospi-
tal stay because of septic shock. Among the major am-
putations in BPG group, 3 were performed in patients
with femoral-popliteal graft (2 PTFE, 1 venous con-
duit), and 11 in infrapopliteal graft (8 PTFE, 3 venous
conduit). Two above-the-knee amputations were per-
formed in non revascularized patients because of
a foot lesion worsening.
Table 4 summarize the number of major amputa-
tions performed in the early and follow-up period.
Fig. 1 shows the Kaplan-Meier curves of major am-
putation in the three groups. The results of multiple
logistic regression analysis performed for the associa-
tion between the recorded variables and the above-
the-ankle amputation are showed in Table 5.
173 (30.7%) patients died during follow-up. 120
(28.9%) patients died in the PTA group, 31 (26.7%)
in the BPG group and 22 (81.4%)in the non-
revascularized group. Fig. 2 shows the Kaplan-Meier
survival curves of the three groups. The causes of
death are reported in Table 6. Table 7 reports the
Hazard Ratio of the Cox model performed for the
association between the recorded variables and
mortality.Eur J Vasc Endovasc Surg Vol 32, November 2006
488 E. Faglia et al.Discussion
In this study patients were enrolled consecutively. No
diabetic patient with TASC parameters of CLI were
excluded. The percentage of patients undergoing re-
vascularization was very high considering that PTA
and BPG were performed in a population enrolled
consecutively and not in selected patients with a pre-
sumed high success of revascularization.12
The high revascularization rate of our cases depends
on the use of both PTA and BPG. Many patients who
underwent PTA were not suitable for BPG because
their three leg arteries or pedal arteries were not patent
or because of the high surgical risk. A high percentage
of patients in whom PTA was not feasible were revas-
cularized with BPG. In our protocol PTA was the
first-choice procedure of revascularization allowing
outcomes similar to BPG.13 In our practice PTA is effec-
tive also in long obstructions of the infrapopliteal ar-
teries.14,15 The in-hospital mortality was very low in
PTA patients, and was also low in BPG patients in com-
parison with the literature data.16
Revascularization is the best therapy to eliminate
pain and heal foot lesion in patients with CLI.17,18
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Fig. 1. Kaplan-Meier above-the-ankle amputation estimates
in PTA, BPG and non revascularized patients.
Table 4. Number of above-the-ankle amputations performed in
the early and follow-up period in PTA, BPG and no revascular-
ized patients
Patients treatment Above-the-ankle amputation Total
At 30 days Follow-up
Angioplasty (N¼ 420) 6 (1.4%) 16 (3.8%) 22 (5.2%)
Bypass graft (N¼ 117) 3 (2.6%) 14 (12%) 17 (14.5%)
No revascularization
(N¼ 27)
14 (51.9%) 2 (7.4%) 16 (59.3%)Eur J Vasc Endovasc Surg Vol 32, November 2006Revascularization is especially necessary when a foot
surgery is required.19,20 The extensive use of revas-
cularization, in association with a good surgical ap-
proach to the foot lesion, resulted in the short period
in a very high rate of limb salvage.2,21,22
However, major amputation were noted during
follow-up. In the PTA group most of the major ampu-
tations were performed for clinical restenosis without
further possibility of endoluminal or surgical revascu-
larisation. All the major amputations of BPG group
were performed because of graft closure. Although
some studies reported a higher rate of pedal by-pass
failure in the early period than in the follow-up,23,24
our data seem to be consistent with the fast progres-
sion of atherosclerosis and the predominantly crural
localization of the atherosclerotic obstructions, which
are typical features in diabetic patients.25,26
The major amputation rate of the non-revascularized
patients is very different. The early major amputation
rate of these patients is very high. The low percentage
during the follow-up can be explained by the very
low survival rate of these patients due the associated
serious comorbid conditions, cardiac especially. The
Table 5. Multiple logistic regression analysis between recorded
variables and above-the-ankle amputation
Variables Odds
ratio
p Confidence
interval
Absence of
revascularization (n)
35.9 <0.001 12.9e99.7
Occlusion of each of the crural
arteries (n)
8.20 0.022 1.35e49.6
Wound infection (n) 2.1 0.004 1.3e3.6
Dialysis (n) 4.7 0.001 1.9e11.7
TcPO2 increase (1 mmHg) 0.80 <0.001 0.74e0.87
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Fig. 2. Kaplan-Meier survival estimates of PTA, BPG and
non revascularized patients.
489Early and Five-year Amputation and Survival Rate of Diabetic Patientsmortality rate is high also in revascularized patients,
although it is lower than in the non-revascularized
patients.27e30
In order to achieve the best health-related quality of
life we aim to avoid major amputation in all patients,
except in patients unable to walk and mentally
incapable.
In conclusion revascularization with PTA or BPG
allows a very high percentage of limb salvage in dia-
betic patients with CLI. In the early period the revas-
cularization, in association with a good medical and
surgical approach to foot lesion, results in a very
high percentage of limb salvage, with very low in hos-
pital mortality rate. During the follow-up the risk of
above-the-ankle amputation is higher, but still lower
compared to the literature data in non-revascularized
patients with CLI.31,32 Impossibility of revasculariza-
tion because of the extent of arterial occlusive disease
or surgical risk is a reliable marker both of a very high
risk of major amputation and of a very low life expec-
tancy, because of the severity of the comorbid condi-
tions associated with the severity of CLI.
Table 7. Cox model for association between recorded variables
and mortality
Variables Hazard
ratio
p Confidence
interval
Age (1 year) 1.05 <0.001 1.03e1.07
History of cardiac
disease (n)
2.16 <0.001 1.53e3.06
Dialysis (n) 3.52 <0.001 2.08e5.97
Absence of
revascularization (n)
1.68 <0.001 1.29e2.19
Impaired ejection
fraction (1%)
1.08 <0.001 1.05e1.09
Table 6. Causes of death in followed population (N[ 558)
Cause of death PTA
N¼ 415
BPG
N¼ 116
No revascularization
N¼ 27
Cardiac disease 64 15 14
Sudden death 12 4 1
Stroke 18 3 4
Cancer 12 5 2
Pulmonary
embolism
e 1 e
Abdominal aneurysm 1 e e
Renal insufficiency 4 e e
Peritonitis 1 e e
Gastric hemorrhage 1 e e
Cirrhosis 2 e e
Pneumonia 2 2 e
Geromarasmus 2 e 1
Septic shock e 1 e
Suicide 1 e e
Total 120 (28.9%) 31 (26.7%) 22 (81.5%)References
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